Showing results (1-10 of 339) with videos related to
Sort By:
Pageof 34
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|July 25, 2009
Pharmaceuticals targeting nonsense mutations in genetic diseases: progress in developmentSteven M Rowe, John P ClancyCurrent Opinion in Pediatrics|November 14, 2006
Advances in cystic fibrosis therapiesSteven M Rowe, John P ClancyProceedings of the American Thoracic Society|July 27, 2007
Detection of cystic fibrosis transmembrane conductance regulator activity in early-phase clinical trialsSteven M Rowe, Frank Accurso, John P ClancyJournal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|June 10, 2020
Changes in LCI in F508del/F508del patients treated with lumacaftor/ivacaftor: Results from the prospect studyMichelle Shaw, Umer Khan, John P Clancy, et al.American Journal of Respiratory Cell and Molecular Biology|June 2, 2007
Restoration of W1282X CFTR activity by enhanced expressionSteven M Rowe, Karoly Varga, Andras Rab, et al.Journal of Pediatric Gastroenterology and Nutrition|April 20, 2022
Changes in Glucose Breath Test in Cystic Fibrosis Patients Treated With 1 Month of Lumacaftor/IvacaftorMegan E Gabel, Hongyue Wang, Daniel Gelfond, et al.Pediatric Pulmonology|October 6, 2018
Rapid therapeutic advances in CFTR modulator scienceJohn P ClancyScience Translational Medicine|August 8, 2014
CFTR potentiators: not an open and shut caseJohn P ClancyThorax|September 11, 2012
Progress in cystic fibrosis and the CF Therapeutics Development NetworkSteven M Rowe, Drucy S Borowitz, Jane L Burns, et al.Future Microbiology|November 18, 2015
Management of Pseudomonas aeruginosa infection in cystic fibrosis patients using inhaled antibiotics with a focus on nebulized liposomal amikacinZarmina Ehsan, John P ClancyPageof 34